#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	event	new	coref	6-1[27_0]

#Text=Tyrosine kinase inhibitors ( TKIs ) are widely used drugs as a targeted strategy for cancer treatment with the aim of prolonging progression-free survival .
3-1	17-25	Tyrosine	abstract|abstract[5]	new|new[5]	appos|coref|appos|coref	3-5[0_5]|4-2|3-5[0_5]|4-2
3-2	26-32	kinase	abstract|abstract[5]	new|new[5]	coref	4-3
3-3	33-43	inhibitors	abstract[5]	new[5]	_	_
3-4	44-45	(	_	_	_	_
3-5	46-50	TKIs	abstract	giv	coref	5-7
3-6	51-52	)	_	_	_	_
3-7	53-56	are	_	_	_	_
3-8	57-63	widely	_	_	_	_
3-9	64-68	used	_	_	_	_
3-10	69-74	drugs	substance	new	coref	11-2[66_0]
3-11	75-77	as	_	_	_	_
3-12	78-79	a	_	_	_	_
3-13	80-88	targeted	_	_	_	_
3-14	89-97	strategy	_	_	_	_
3-15	98-101	for	_	_	_	_
3-16	102-108	cancer	abstract|event[9]	new|new[9]	coref|coref	5-13[25_9]|5-13[25_9]
3-17	109-118	treatment	event[9]	new[9]	_	_
3-18	119-123	with	event[9]	new[9]	_	_
3-19	124-127	the	event[9]|abstract[10]	new[9]|new[10]	_	_
3-20	128-131	aim	event[9]|abstract[10]	new[9]|new[10]	_	_
3-21	132-134	of	_	_	_	_
3-22	135-145	prolonging	_	_	_	_
3-23	146-162	progression-free	event[11]	new[11]	coref	6-30[36_11]
3-24	163-171	survival	event[11]	new[11]	_	_
3-25	172-173	.	_	_	_	_

#Text=Deregulated tyrosine kinase activity of the BCR-ABL oncoprotein is the biochemical hallmark of Philadelphia chromosome-positive ( Ph+ ) hematological malignancies .
4-1	174-185	Deregulated	abstract[14]	new[14]	coref	4-10[17_14]
4-2	186-194	tyrosine	abstract|abstract[14]	giv|new[14]	coref	11-28
4-3	195-201	kinase	abstract|abstract[14]	giv|new[14]	coref	11-12
4-4	202-210	activity	abstract[14]	new[14]	_	_
4-5	211-213	of	abstract[14]	new[14]	_	_
4-6	214-217	the	abstract[14]|substance[16]	new[14]|new[16]	_	_
4-7	218-225	BCR-ABL	abstract[14]|abstract|substance[16]	new[14]|new|new[16]	coref	5-6
4-8	226-237	oncoprotein	abstract[14]|substance[16]	new[14]|new[16]	_	_
4-9	238-240	is	_	_	_	_
4-10	241-244	the	abstract[17]	giv[17]	_	_
4-11	245-256	biochemical	abstract[17]	giv[17]	_	_
4-12	257-265	hallmark	abstract[17]	giv[17]	_	_
4-13	266-268	of	abstract[17]	giv[17]	_	_
4-14	269-281	Philadelphia	abstract[17]|person|event[20]	giv[17]|new|new[20]	coref|coref	5-15[26_20]|5-15[26_20]
4-15	282-301	chromosome-positive	abstract[17]|event[20]	giv[17]|new[20]	_	_
4-16	302-303	(	abstract[17]|event[20]	giv[17]|new[20]	_	_
4-17	304-307	Ph+	abstract[17]|abstract|event[20]	giv[17]|new|new[20]	coref	8-3
4-18	308-309	)	abstract[17]|event[20]	giv[17]|new[20]	_	_
4-19	310-323	hematological	abstract[17]|event[20]	giv[17]|new[20]	_	_
4-20	324-336	malignancies	abstract[17]|event[20]	giv[17]|new[20]	_	_
4-21	337-338	.	_	_	_	_

#Text=Currently , several generations of BCR-ABL TKIs are in clinical use for treatment of these malignancies .
5-1	339-348	Currently	_	_	_	_
5-2	349-350	,	_	_	_	_
5-3	351-358	several	abstract[21]	new[21]	_	_
5-4	359-370	generations	abstract[21]	new[21]	_	_
5-5	371-373	of	abstract[21]	new[21]	_	_
5-6	374-381	BCR-ABL	abstract[21]|abstract	new[21]|giv	coref	22-14
5-7	382-386	TKIs	abstract[21]|abstract	new[21]|giv	coref	6-3[28_0]
5-8	387-390	are	_	_	_	_
5-9	391-393	in	_	_	_	_
5-10	394-402	clinical	abstract[24]	new[24]	_	_
5-11	403-406	use	abstract[24]	new[24]	_	_
5-12	407-410	for	abstract[24]	new[24]	_	_
5-13	411-420	treatment	abstract[24]|event[25]	new[24]|giv[25]	coref	7-16[41_25]
5-14	421-423	of	abstract[24]|event[25]	new[24]|giv[25]	_	_
5-15	424-429	these	abstract[24]|event[25]|event[26]	new[24]|giv[25]|giv[26]	_	_
5-16	430-442	malignancies	abstract[24]|event[25]|event[26]	new[24]|giv[25]|giv[26]	_	_
5-17	443-444	.	_	_	_	_

#Text=Introduction of the second-generation TKIs , nilotinib and dasatinib as first-line treatment resulted in rapid and deep reduction of BCR/ABL1 allele transcripts , and this provided a possibility for long-term survival in CML .
6-1	445-457	Introduction	event[27]	giv[27]	_	_
6-2	458-460	of	event[27]	giv[27]	_	_
6-3	461-464	the	event[27]|abstract[28]	giv[27]|giv[28]	coref	9-13[51_28]
6-4	465-482	second-generation	event[27]|abstract[28]	giv[27]|giv[28]	_	_
6-5	483-487	TKIs	event[27]|abstract[28]	giv[27]|giv[28]	_	_
6-6	488-489	,	event[27]|abstract[28]	giv[27]|giv[28]	_	_
6-7	490-499	nilotinib	event[27]|abstract[28]|substance	giv[27]|giv[28]|new	coref	10-14
6-8	500-503	and	event[27]|abstract[28]	giv[27]|giv[28]	_	_
6-9	504-513	dasatinib	event[27]|abstract[28]|substance[30]	giv[27]|giv[28]|new[30]	coref	10-21[0_30]
6-10	514-516	as	event[27]|abstract[28]|substance[30]	giv[27]|giv[28]|new[30]	_	_
6-11	517-527	first-line	event[27]|abstract[28]|substance[30]	giv[27]|giv[28]|new[30]	_	_
6-12	528-537	treatment	event[27]|abstract[28]|substance[30]	giv[27]|giv[28]|new[30]	_	_
6-13	538-546	resulted	_	_	_	_
6-14	547-549	in	_	_	_	_
6-15	550-555	rapid	abstract[31]	new[31]	ana	6-25[0_31]
6-16	556-559	and	abstract[31]	new[31]	_	_
6-17	560-564	deep	abstract[31]	new[31]	_	_
6-18	565-574	reduction	abstract[31]	new[31]	_	_
6-19	575-577	of	abstract[31]	new[31]	_	_
6-20	578-586	BCR/ABL1	abstract[31]|object|object[33]	new[31]|new|new[33]	_	_
6-21	587-593	allele	abstract[31]|object[33]	new[31]|new[33]	_	_
6-22	594-605	transcripts	abstract[31]|object[33]	new[31]|new[33]	_	_
6-23	606-607	,	_	_	_	_
6-24	608-611	and	_	_	_	_
6-25	612-616	this	abstract	giv	_	_
6-26	617-625	provided	_	_	_	_
6-27	626-627	a	abstract[35]	new[35]	_	_
6-28	628-639	possibility	abstract[35]	new[35]	_	_
6-29	640-643	for	abstract[35]	new[35]	_	_
6-30	644-653	long-term	abstract[35]|event[36]	new[35]|giv[36]	_	_
6-31	654-662	survival	abstract[35]|event[36]	new[35]|giv[36]	_	_
6-32	663-665	in	abstract[35]|event[36]	new[35]|giv[36]	_	_
6-33	666-669	CML	abstract[35]|event[36]|abstract	new[35]|giv[36]|new	coref	7-4
6-34	670-671	.	_	_	_	_

#Text=In addition to CML , several other patient populations were identified that undoubtedly benefited from TKI treatment .
7-1	672-674	In	_	_	_	_
7-2	675-683	addition	_	_	_	_
7-3	684-686	to	_	_	_	_
7-4	687-690	CML	abstract	giv	coref	29-32
7-5	691-692	,	_	_	_	_
7-6	693-700	several	person[39]	new[39]	_	_
7-7	701-706	other	person[39]	new[39]	_	_
7-8	707-714	patient	person[39]	new[39]	_	_
7-9	715-726	populations	person[39]	new[39]	_	_
7-10	727-731	were	_	_	_	_
7-11	732-742	identified	_	_	_	_
7-12	743-747	that	_	_	_	_
7-13	748-759	undoubtedly	_	_	_	_
7-14	760-769	benefited	_	_	_	_
7-15	770-774	from	_	_	_	_
7-16	775-778	TKI	event|event[41]	new|giv[41]	coref|coref	8-17|8-17
7-17	779-788	treatment	event[41]	giv[41]	_	_
7-18	789-790	.	_	_	_	_

#Text=Patients with Ph+ adult acute lymphoblastic leukemia ( ALL ) may also benefit from an alternate TKI therapy .
8-1	791-799	Patients	abstract[42]	new[42]	_	_
8-2	800-804	with	abstract[42]	new[42]	_	_
8-3	805-808	Ph+	abstract[42]|abstract|abstract[44]	new[42]|giv|new[44]	coref|coref	9-8|9-8
8-4	809-814	adult	abstract[42]|abstract[44]	new[42]|new[44]	_	_
8-5	815-820	acute	abstract[42]|abstract[44]	new[42]|new[44]	_	_
8-6	821-834	lymphoblastic	abstract[42]|abstract[44]	new[42]|new[44]	_	_
8-7	835-843	leukemia	abstract[42]|abstract[44]	new[42]|new[44]	_	_
8-8	844-845	(	_	_	_	_
8-9	846-849	ALL	_	_	_	_
8-10	850-851	)	_	_	_	_
8-11	852-855	may	_	_	_	_
8-12	856-860	also	_	_	_	_
8-13	861-868	benefit	_	_	_	_
8-14	869-873	from	_	_	_	_
8-15	874-876	an	abstract[46]	new[46]	_	_
8-16	877-886	alternate	abstract[46]	new[46]	_	_
8-17	887-890	TKI	abstract|abstract[46]	giv|new[46]	_	_
8-18	891-898	therapy	abstract[46]	new[46]	_	_
8-19	899-900	.	_	_	_	_

#Text=In the treatment of pediatric patients with Ph+ ALL the addition of TKIs to conventional chemotherapy has improved outcomes of patients .
9-1	901-903	In	_	_	_	_
9-2	904-907	the	abstract[47]	new[47]	_	_
9-3	908-917	treatment	abstract[47]	new[47]	_	_
9-4	918-920	of	abstract[47]	new[47]	_	_
9-5	921-930	pediatric	abstract[47]|person[48]	new[47]|new[48]	coref	9-21[0_48]
9-6	931-939	patients	abstract[47]|person[48]	new[47]|new[48]	_	_
9-7	940-944	with	abstract[47]|person[48]	new[47]|new[48]	_	_
9-8	945-948	Ph+	abstract[47]|person[48]|abstract	new[47]|new[48]|giv	_	_
9-9	949-952	ALL	abstract[50]	new[50]	_	_
9-10	953-956	the	abstract[50]	new[50]	_	_
9-11	957-965	addition	abstract[50]	new[50]	_	_
9-12	966-968	of	abstract[50]	new[50]	_	_
9-13	969-973	TKIs	abstract[50]|abstract[51]	new[50]|giv[51]	coref	10-7[56_51]
9-14	974-976	to	abstract[50]|abstract[51]	new[50]|giv[51]	_	_
9-15	977-989	conventional	abstract[50]|abstract[51]|abstract[52]	new[50]|giv[51]|new[52]	ana	10-1[0_52]
9-16	990-1002	chemotherapy	abstract[50]|abstract[51]|abstract[52]	new[50]|giv[51]|new[52]	_	_
9-17	1003-1006	has	_	_	_	_
9-18	1007-1015	improved	_	_	_	_
9-19	1016-1024	outcomes	abstract[53]	new[53]	_	_
9-20	1025-1027	of	abstract[53]	new[53]	_	_
9-21	1028-1036	patients	abstract[53]|person	new[53]|giv	ana	11-18
9-22	1037-1038	.	_	_	_	_

#Text=It has long been known that second-generation TKIs may have side effects as nilotinib can potentiate a prothrombotic state while dasatinib is known to cause platelet dysfunction e.g. impaired collagen-induced platelet adhesion and aggregation .
10-1	1039-1041	It	abstract	giv	_	_
10-2	1042-1045	has	_	_	_	_
10-3	1046-1050	long	_	_	_	_
10-4	1051-1055	been	_	_	_	_
10-5	1056-1061	known	_	_	_	_
10-6	1062-1066	that	_	_	_	_
10-7	1067-1084	second-generation	abstract[56]	giv[56]	coref	21-1[0_56]
10-8	1085-1089	TKIs	abstract[56]	giv[56]	_	_
10-9	1090-1093	may	_	_	_	_
10-10	1094-1098	have	_	_	_	_
10-11	1099-1103	side	abstract[57]	new[57]	coref	22-9[150_57]
10-12	1104-1111	effects	abstract[57]	new[57]	_	_
10-13	1112-1114	as	_	_	_	_
10-14	1115-1124	nilotinib	substance	giv	coref	13-1
10-15	1125-1128	can	_	_	_	_
10-16	1129-1139	potentiate	_	_	_	_
10-17	1140-1141	a	abstract[59]	new[59]	_	_
10-18	1142-1155	prothrombotic	abstract[59]	new[59]	_	_
10-19	1156-1161	state	abstract[59]	new[59]	_	_
10-20	1162-1167	while	_	_	_	_
10-21	1168-1177	dasatinib	substance	giv	coref	12-1
10-22	1178-1180	is	_	_	_	_
10-23	1181-1186	known	_	_	_	_
10-24	1187-1189	to	_	_	_	_
10-25	1190-1195	cause	_	_	_	_
10-26	1196-1204	platelet	object|abstract[62]	new|new[62]	coref|coref	10-31|10-31
10-27	1205-1216	dysfunction	abstract[62]	new[62]	_	_
10-28	1217-1221	e.g.	_	_	_	_
10-29	1222-1230	impaired	_	_	_	_
10-30	1231-1247	collagen-induced	abstract[64]	new[64]	_	_
10-31	1248-1256	platelet	object|abstract[64]	giv|new[64]	coref	14-14
10-32	1257-1265	adhesion	abstract[64]	new[64]	_	_
10-33	1266-1269	and	_	_	_	_
10-34	1270-1281	aggregation	event	new	coref	14-12[102_0]
10-35	1282-1283	.	_	_	_	_

#Text=Although both drugs bind to the ATP binding site of the kinase domain of the BCR/ABL protein they have different off target inhibitory effect on several other tyrosine kinases .
11-1	1284-1292	Although	_	_	_	_
11-2	1293-1297	both	substance[66]	giv[66]	_	_
11-3	1298-1303	drugs	substance[66]	giv[66]	_	_
11-4	1304-1308	bind	_	_	_	_
11-5	1309-1311	to	_	_	_	_
11-6	1312-1315	the	place[69]	new[69]	_	_
11-7	1316-1319	ATP	abstract|place[69]	new|new[69]	_	_
11-8	1320-1327	binding	object|place[69]	new|new[69]	coref	26-6[181_0]
11-9	1328-1332	site	place[69]	new[69]	_	_
11-10	1333-1335	of	place[69]	new[69]	_	_
11-11	1336-1339	the	place[69]|place[71]	new[69]|new[71]	_	_
11-12	1340-1346	kinase	place[69]|abstract|place[71]	new[69]|giv|new[71]	coref	23-23[162_0]
11-13	1347-1353	domain	place[69]|place[71]	new[69]|new[71]	_	_
11-14	1354-1356	of	place[69]|place[71]	new[69]|new[71]	_	_
11-15	1357-1360	the	place[69]|place[71]|object[73]	new[69]|new[71]|new[73]	_	_
11-16	1361-1368	BCR/ABL	place[69]|place[71]|object|object[73]	new[69]|new[71]|new|new[73]	_	_
11-17	1369-1376	protein	place[69]|place[71]|object[73]	new[69]|new[71]|new[73]	_	_
11-18	1377-1381	they	person	giv	coref	29-32[210_0]
11-19	1382-1386	have	_	_	_	_
11-20	1387-1396	different	abstract[76]	new[76]	coref	15-6[104_76]
11-21	1397-1400	off	abstract[76]	new[76]	_	_
11-22	1401-1407	target	abstract|abstract[76]	new|new[76]	_	_
11-23	1408-1418	inhibitory	abstract[76]	new[76]	_	_
11-24	1419-1425	effect	abstract[76]	new[76]	_	_
11-25	1426-1428	on	abstract[76]	new[76]	_	_
11-26	1429-1436	several	abstract[76]|abstract[78]	new[76]|new[78]	coref	13-14[92_78]
11-27	1437-1442	other	abstract[76]|abstract[78]	new[76]|new[78]	_	_
11-28	1443-1451	tyrosine	abstract[76]|abstract|abstract[78]	new[76]|giv|new[78]	coref	13-15
11-29	1452-1459	kinases	abstract[76]|abstract[78]	new[76]|new[78]	_	_
11-30	1460-1461	.	_	_	_	_

#Text=Dasatinib is a potent multikinase inhibitor , including c-KIT , EPHA2 , platelet-derived growth factor receptor-β , and SFKs .
12-1	1462-1471	Dasatinib	abstract	giv	coref	12-3[80_0]
12-2	1472-1474	is	_	_	_	_
12-3	1475-1476	a	abstract[80]	giv[80]	coref	14-9[0_80]
12-4	1477-1483	potent	abstract[80]	giv[80]	_	_
12-5	1484-1495	multikinase	abstract[80]	giv[80]	_	_
12-6	1496-1505	inhibitor	abstract[80]	giv[80]	_	_
12-7	1506-1507	,	abstract[80]	giv[80]	_	_
12-8	1508-1517	including	abstract[80]	giv[80]	_	_
12-9	1518-1523	c-KIT	abstract[80]|substance	giv[80]|new	coref	13-20
12-10	1524-1525	,	abstract[80]	giv[80]	_	_
12-11	1526-1531	EPHA2	abstract[80]|object	giv[80]|new	_	_
12-12	1532-1533	,	abstract[80]	giv[80]	_	_
12-13	1534-1550	platelet-derived	abstract[80]|abstract[83]|abstract[85]	giv[80]|new[83]|new[85]	_	_
12-14	1551-1557	growth	abstract[80]|abstract[83]|abstract[85]	giv[80]|new[83]|new[85]	_	_
12-15	1558-1564	factor	abstract[80]|abstract|abstract[85]	giv[80]|new|new[85]	_	_
12-16	1565-1575	receptor-β	abstract[80]|abstract[85]	giv[80]|new[85]	_	_
12-17	1576-1577	,	abstract[80]	giv[80]	_	_
12-18	1578-1581	and	abstract[80]	giv[80]	_	_
12-19	1582-1586	SFKs	abstract[80]|place	giv[80]|new	coref	13-32
12-20	1587-1588	.	_	_	_	_

#Text=Nilotinib is also a second generation TKI with a broad inhibitory spectrum of various tyrosine kinases ( PDGFR , c-KIT , ARG , EPHB4 ) , but it does not inhibit SFKs .
13-1	1589-1598	Nilotinib	abstract	giv	coref	13-4[88_0]
13-2	1599-1601	is	_	_	_	_
13-3	1602-1606	also	_	_	_	_
13-4	1607-1608	a	abstract[88]	giv[88]	appos	13-7[89_88]
13-5	1609-1615	second	abstract[88]	giv[88]	_	_
13-6	1616-1626	generation	abstract[88]	giv[88]	_	_
13-7	1627-1630	TKI	abstract[89]	giv[89]	coref	15-2[103_89]
13-8	1631-1635	with	abstract[89]	giv[89]	_	_
13-9	1636-1637	a	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
13-10	1638-1643	broad	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
13-11	1644-1654	inhibitory	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
13-12	1655-1663	spectrum	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
13-13	1664-1666	of	abstract[89]|abstract[90]	giv[89]|new[90]	_	_
13-14	1667-1674	various	abstract[89]|abstract[90]|abstract[92]	giv[89]|new[90]|giv[92]	appos	13-18[94_92]
13-15	1675-1683	tyrosine	abstract[89]|abstract[90]|abstract|abstract[92]	giv[89]|new[90]|giv|giv[92]	_	_
13-16	1684-1691	kinases	abstract[89]|abstract[90]|abstract[92]	giv[89]|new[90]|giv[92]	_	_
13-17	1692-1693	(	_	_	_	_
13-18	1694-1699	PDGFR	object|abstract[94]	new|giv[94]	coref|coref	18-1[119_94]|18-1[119_94]
13-19	1700-1701	,	abstract[94]	giv[94]	_	_
13-20	1702-1707	c-KIT	abstract[94]|abstract	giv[94]|giv	_	_
13-21	1708-1709	,	abstract[94]	giv[94]	_	_
13-22	1710-1713	ARG	abstract[94]	giv[94]	_	_
13-23	1714-1715	,	_	_	_	_
13-24	1716-1721	EPHB4	abstract	new	ana	13-28
13-25	1722-1723	)	_	_	_	_
13-26	1724-1725	,	_	_	_	_
13-27	1726-1729	but	_	_	_	_
13-28	1730-1732	it	abstract	giv	_	_
13-29	1733-1737	does	_	_	_	_
13-30	1738-1741	not	_	_	_	_
13-31	1742-1749	inhibit	_	_	_	_
13-32	1750-1754	SFKs	abstract	giv	coref	17-5
13-33	1755-1756	.	_	_	_	_

#Text=Previous in vitro and ex vivo studies with dasatinib have demonstrated a faulty platelet aggregation .
14-1	1757-1765	Previous	_	_	_	_
14-2	1766-1768	in	_	_	_	_
14-3	1769-1774	vitro	_	_	_	_
14-4	1775-1778	and	_	_	_	_
14-5	1779-1781	ex	_	_	_	_
14-6	1782-1786	vivo	event[99]	new[99]	_	_
14-7	1787-1794	studies	event[99]	new[99]	_	_
14-8	1795-1799	with	event[99]	new[99]	_	_
14-9	1800-1809	dasatinib	event[99]|substance	new[99]|giv	coref	28-6
14-10	1810-1814	have	_	_	_	_
14-11	1815-1827	demonstrated	_	_	_	_
14-12	1828-1829	a	event[102]	giv[102]	coref	15-9[106_102]
14-13	1830-1836	faulty	event[102]	giv[102]	_	_
14-14	1837-1845	platelet	object|event[102]	giv|giv[102]	coref	15-9
14-15	1846-1857	aggregation	event[102]	giv[102]	_	_
14-16	1858-1859	.	_	_	_	_

#Text=On the contrary nilotinib has no effect on platelet aggregation , at all .
15-1	1860-1862	On	_	_	_	_
15-2	1863-1866	the	substance[103]	giv[103]	coref	16-5[0_103]
15-3	1867-1875	contrary	substance[103]	giv[103]	_	_
15-4	1876-1885	nilotinib	substance[103]	giv[103]	_	_
15-5	1886-1889	has	_	_	_	_
15-6	1890-1892	no	abstract[104]	giv[104]	coref	21-3[146_104]
15-7	1893-1899	effect	abstract[104]	giv[104]	_	_
15-8	1900-1902	on	abstract[104]	giv[104]	_	_
15-9	1903-1911	platelet	abstract[104]|object|event[106]	giv[104]|giv|giv[106]	ana|coref|ana|coref	15-13[0_106]|17-11|15-13[0_106]|17-11
15-10	1912-1923	aggregation	abstract[104]|event[106]	giv[104]|giv[106]	_	_
15-11	1924-1925	,	_	_	_	_
15-12	1926-1928	at	_	_	_	_
15-13	1929-1932	all	event	giv	coref	24-16[171_0]
15-14	1933-1934	.	_	_	_	_

#Text=Therefore , we used nilotinib as a negative control in our experiments .
16-1	1935-1944	Therefore	_	_	_	_
16-2	1945-1946	,	_	_	_	_
16-3	1947-1949	we	person	acc	ana	16-11
16-4	1950-1954	used	_	_	_	_
16-5	1955-1964	nilotinib	substance	giv	coref	23-31
16-6	1965-1967	as	_	_	_	_
16-7	1968-1969	a	_	_	_	_
16-8	1970-1978	negative	_	_	_	_
16-9	1979-1986	control	_	_	_	_
16-10	1987-1989	in	_	_	_	_
16-11	1990-1993	our	person|abstract[111]	giv|new[111]	ana|ana	28-1|28-1
16-12	1994-2005	experiments	abstract[111]	new[111]	_	_
16-13	2006-2007	.	_	_	_	_

#Text=Sarcoma family kinases ( SFKs ) are critical regulators of platelet signaling and activation .
17-1	2008-2015	Sarcoma	abstract|person[113]	new|new[113]	_	_
17-2	2016-2022	family	person[113]	new[113]	_	_
17-3	2023-2030	kinases	_	_	_	_
17-4	2031-2032	(	_	_	_	_
17-5	2033-2037	SFKs	abstract	giv	coref	20-11
17-6	2038-2039	)	_	_	_	_
17-7	2040-2043	are	_	_	_	_
17-8	2044-2052	critical	substance[115]	new[115]	_	_
17-9	2053-2063	regulators	substance[115]	new[115]	_	_
17-10	2064-2066	of	substance[115]	new[115]	_	_
17-11	2067-2075	platelet	substance[115]|object|abstract[117]	new[115]|giv|new[117]	coref|coref|coref|coref	19-8|20-28[140_117]|19-8|20-28[140_117]
17-12	2076-2085	signaling	substance[115]|abstract[117]	new[115]|new[117]	_	_
17-13	2086-2089	and	substance[115]	new[115]	_	_
17-14	2090-2100	activation	substance[115]|event	new[115]|new	coref	19-3
17-15	2101-2102	.	_	_	_	_

#Text=These kinases play a central role in mediating rapid response of platelets to vascular injury .
18-1	2103-2108	These	abstract[119]	giv[119]	coref	23-18[0_119]
18-2	2109-2116	kinases	abstract[119]	giv[119]	_	_
18-3	2117-2121	play	_	_	_	_
18-4	2122-2123	a	abstract[120]	new[120]	_	_
18-5	2124-2131	central	abstract[120]	new[120]	_	_
18-6	2132-2136	role	abstract[120]	new[120]	_	_
18-7	2137-2139	in	_	_	_	_
18-8	2140-2149	mediating	_	_	_	_
18-9	2150-2155	rapid	abstract[121]	new[121]	coref	29-17[204_121]
18-10	2156-2164	response	abstract[121]	new[121]	_	_
18-11	2165-2167	of	abstract[121]	new[121]	_	_
18-12	2168-2177	platelets	abstract[121]|object	new[121]|new	ana	19-1
18-13	2178-2180	to	_	_	_	_
18-14	2181-2189	vascular	event[123]	new[123]	coref	24-2[166_123]
18-15	2190-2196	injury	event[123]	new[123]	_	_
18-16	2197-2198	.	_	_	_	_

#Text=They transmit activation signals from several various platelet receptors .
19-1	2199-2203	They	object	giv	coref	20-42[143_0]
19-2	2204-2212	transmit	_	_	_	_
19-3	2213-2223	activation	abstract|abstract[126]	giv|new[126]	coref|coref	20-22[135_0]|20-22[135_0]
19-4	2224-2231	signals	abstract[126]	new[126]	_	_
19-5	2232-2236	from	_	_	_	_
19-6	2237-2244	several	object[128]	new[128]	_	_
19-7	2245-2252	various	object[128]	new[128]	_	_
19-8	2253-2261	platelet	object|object[128]	giv|new[128]	coref	24-17
19-9	2262-2271	receptors	object[128]	new[128]	_	_
19-10	2272-2273	.	_	_	_	_

#Text=There are numerous members of this group and among the SFKs Lyn , Fyn , and Src have been implicated in activation of the GPVI receptor and the integrin receptor signaling and are frequently studied proteins as they are present in both human and mouse platelets .
20-1	2274-2279	There	_	_	_	_
20-2	2280-2283	are	_	_	_	_
20-3	2284-2292	numerous	person[129]	new[129]	ana	20-38[0_129]
20-4	2293-2300	members	person[129]	new[129]	_	_
20-5	2301-2303	of	person[129]	new[129]	_	_
20-6	2304-2308	this	person[129]|abstract[130]	new[129]|new[130]	_	_
20-7	2309-2314	group	person[129]|abstract[130]	new[129]|new[130]	_	_
20-8	2315-2318	and	_	_	_	_
20-9	2319-2324	among	_	_	_	_
20-10	2325-2328	the	person[132]	new[132]	coref	23-11[0_132]
20-11	2329-2333	SFKs	place|person[132]	giv|new[132]	coref	23-5[154_0]
20-12	2334-2337	Lyn	person[132]	new[132]	_	_
20-13	2338-2339	,	_	_	_	_
20-14	2340-2343	Fyn	abstract	new	_	_
20-15	2344-2345	,	_	_	_	_
20-16	2346-2349	and	_	_	_	_
20-17	2350-2353	Src	abstract	new	coref	23-16
20-18	2354-2358	have	_	_	_	_
20-19	2359-2363	been	_	_	_	_
20-20	2364-2374	implicated	_	_	_	_
20-21	2375-2377	in	_	_	_	_
20-22	2378-2388	activation	event[135]	giv[135]	_	_
20-23	2389-2391	of	event[135]	giv[135]	_	_
20-24	2392-2395	the	event[135]|substance[137]	giv[135]|new[137]	coref	20-30[0_137]
20-25	2396-2400	GPVI	event[135]|abstract|substance[137]	giv[135]|new|new[137]	_	_
20-26	2401-2409	receptor	event[135]|substance[137]	giv[135]|new[137]	_	_
20-27	2410-2413	and	event[135]	giv[135]	_	_
20-28	2414-2417	the	event[135]|abstract[140]	giv[135]|giv[140]	_	_
20-29	2418-2426	integrin	event[135]|person|abstract[140]	giv[135]|new|giv[140]	_	_
20-30	2427-2435	receptor	event[135]|substance|abstract[140]	giv[135]|giv|giv[140]	_	_
20-31	2436-2445	signaling	event[135]|abstract[140]	giv[135]|giv[140]	_	_
20-32	2446-2449	and	_	_	_	_
20-33	2450-2453	are	_	_	_	_
20-34	2454-2464	frequently	_	_	_	_
20-35	2465-2472	studied	_	_	_	_
20-36	2473-2481	proteins	substance	new	_	_
20-37	2482-2484	as	_	_	_	_
20-38	2485-2489	they	person	giv	_	_
20-39	2490-2493	are	_	_	_	_
20-40	2494-2501	present	_	_	_	_
20-41	2502-2504	in	_	_	_	_
20-42	2505-2509	both	object[143]	giv[143]	coref	24-12[169_143]
20-43	2510-2515	human	object[143]	giv[143]	_	_
20-44	2516-2519	and	object[143]	giv[143]	_	_
20-45	2520-2525	mouse	object[143]	giv[143]	_	_
20-46	2526-2535	platelets	object[143]	giv[143]	_	_
20-47	2536-2537	.	_	_	_	_

#Text=TKIs have a different off-target multikinase inhibitory effect .
21-1	2538-2542	TKIs	event	giv	coref	22-15
21-2	2543-2547	have	_	_	_	_
21-3	2548-2549	a	abstract[146]	giv[146]	coref	30-14[216_146]
21-4	2550-2559	different	abstract[146]	giv[146]	_	_
21-5	2560-2570	off-target	abstract[146]	giv[146]	_	_
21-6	2571-2582	multikinase	abstract[146]	giv[146]	_	_
21-7	2583-2593	inhibitory	abstract|abstract[146]	new|giv[146]	_	_
21-8	2594-2600	effect	abstract[146]	giv[146]	_	_
21-9	2601-2602	.	_	_	_	_

#Text=Comprehensive drug-protein interaction profiles were described to predict the potential side effects of BCR-ABL TKIs .
22-1	2603-2616	Comprehensive	abstract[148]	new[148]	_	_
22-2	2617-2629	drug-protein	abstract[148]	new[148]	_	_
22-3	2630-2641	interaction	abstract|abstract[148]	new|new[148]	_	_
22-4	2642-2650	profiles	abstract[148]	new[148]	_	_
22-5	2651-2655	were	_	_	_	_
22-6	2656-2665	described	_	_	_	_
22-7	2666-2668	to	_	_	_	_
22-8	2669-2676	predict	_	_	_	_
22-9	2677-2680	the	abstract[150]	giv[150]	_	_
22-10	2681-2690	potential	abstract[150]	giv[150]	_	_
22-11	2691-2695	side	abstract|abstract[150]	new|giv[150]	_	_
22-12	2696-2703	effects	abstract[150]	giv[150]	_	_
22-13	2704-2706	of	abstract[150]	giv[150]	_	_
22-14	2707-2714	BCR-ABL	abstract[150]|abstract	giv[150]|giv	_	_
22-15	2715-2719	TKIs	abstract[150]|abstract	giv[150]|giv	ana	23-1
22-16	2720-2721	.	_	_	_	_

#Text=It was found that the most prominent dasatinib-targeted SFKs are Lyn , Fyn , and Src , kinases and their negative regulator C-terminal Src kinase ( Csk ) , but nilotinib does not bind to these kinases .
23-1	2722-2724	It	abstract	giv	_	_
23-2	2725-2728	was	_	_	_	_
23-3	2729-2734	found	_	_	_	_
23-4	2735-2739	that	_	_	_	_
23-5	2740-2743	the	place[154]	giv[154]	coref	23-11[156_154]
23-6	2744-2748	most	place[154]	giv[154]	_	_
23-7	2749-2758	prominent	place[154]	giv[154]	_	_
23-8	2759-2777	dasatinib-targeted	place[154]	giv[154]	_	_
23-9	2778-2782	SFKs	place[154]	giv[154]	_	_
23-10	2783-2786	are	_	_	_	_
23-11	2787-2790	Lyn	person|place[156]	giv|giv[156]	_	_
23-12	2791-2792	,	place[156]	giv[156]	_	_
23-13	2793-2796	Fyn	place[156]|person	giv[156]|new	_	_
23-14	2797-2798	,	place[156]	giv[156]	_	_
23-15	2799-2802	and	place[156]	giv[156]	_	_
23-16	2803-2806	Src	place[156]|abstract	giv[156]|giv	coref	23-24
23-17	2807-2808	,	place[156]	giv[156]	_	_
23-18	2809-2816	kinases	place[156]|abstract	giv[156]|giv	coref	23-36[165_0]
23-19	2817-2820	and	place[156]	giv[156]	_	_
23-20	2821-2826	their	place[156]|substance[160]	giv[156]|new[160]	_	_
23-21	2827-2835	negative	place[156]|substance[160]	giv[156]|new[160]	_	_
23-22	2836-2845	regulator	place[156]|substance[160]	giv[156]|new[160]	_	_
23-23	2846-2856	C-terminal	place[156]|abstract[162]	giv[156]|giv[162]	_	_
23-24	2857-2860	Src	place[156]|abstract|abstract[162]	giv[156]|giv|giv[162]	_	_
23-25	2861-2867	kinase	place[156]|abstract[162]	giv[156]|giv[162]	_	_
23-26	2868-2869	(	_	_	_	_
23-27	2870-2873	Csk	organization	new	_	_
23-28	2874-2875	)	_	_	_	_
23-29	2876-2877	,	_	_	_	_
23-30	2878-2881	but	_	_	_	_
23-31	2882-2891	nilotinib	substance	giv	ana	24-4
23-32	2892-2896	does	_	_	_	_
23-33	2897-2900	not	_	_	_	_
23-34	2901-2905	bind	_	_	_	_
23-35	2906-2908	to	_	_	_	_
23-36	2909-2914	these	abstract[165]	giv[165]	_	_
23-37	2915-2922	kinases	abstract[165]	giv[165]	_	_
23-38	2923-2924	.	_	_	_	_

#Text=During vascular injury it is primarily the subendothelial collagen that activates platelets and result in subsequent platelet aggregation .
24-1	2925-2931	During	_	_	_	_
24-2	2932-2940	vascular	event[166]	giv[166]	_	_
24-3	2941-2947	injury	event[166]	giv[166]	_	_
24-4	2948-2950	it	object	giv	coref	24-6[168_0]
24-5	2951-2953	is	_	_	_	_
24-6	2954-2963	primarily	object[168]	giv[168]	coref	26-15[185_168]
24-7	2964-2967	the	object[168]	giv[168]	_	_
24-8	2968-2982	subendothelial	object[168]	giv[168]	_	_
24-9	2983-2991	collagen	object[168]	giv[168]	_	_
24-10	2992-2996	that	_	_	_	_
24-11	2997-3006	activates	_	_	_	_
24-12	3007-3016	platelets	object[169]	giv[169]	coref	25-4[173_169]
24-13	3017-3020	and	object[169]	giv[169]	_	_
24-14	3021-3027	result	object[169]	giv[169]	_	_
24-15	3028-3030	in	object[169]	giv[169]	_	_
24-16	3031-3041	subsequent	object[169]|event[171]	giv[169]|giv[171]	_	_
24-17	3042-3050	platelet	object[169]|object|event[171]	giv[169]|giv|giv[171]	coref	28-10
24-18	3051-3062	aggregation	object[169]|event[171]	giv[169]|giv[171]	_	_
24-19	3063-3064	.	_	_	_	_

#Text=A population of the collagen-adhered platelets responds by surface exposure of the procoagulant phosphatidylserine ( PS ) .
25-1	3065-3066	A	abstract[172]	new[172]	_	_
25-2	3067-3077	population	abstract[172]	new[172]	_	_
25-3	3078-3080	of	abstract[172]	new[172]	_	_
25-4	3081-3084	the	abstract[172]|object[173]	new[172]|giv[173]	coref	27-4[0_173]
25-5	3085-3101	collagen-adhered	abstract[172]|object[173]	new[172]|giv[173]	_	_
25-6	3102-3111	platelets	abstract[172]|object[173]	new[172]|giv[173]	_	_
25-7	3112-3120	responds	_	_	_	_
25-8	3121-3123	by	_	_	_	_
25-9	3124-3131	surface	place|abstract[175]	new|new[175]	coref|coref	26-1[179_0]|26-1[179_0]
25-10	3132-3140	exposure	abstract[175]	new[175]	_	_
25-11	3141-3143	of	abstract[175]	new[175]	_	_
25-12	3144-3147	the	abstract[175]|substance[177]	new[175]|new[177]	_	_
25-13	3148-3160	procoagulant	abstract[175]|object|substance[177]	new[175]|new|new[177]	coref	28-11
25-14	3161-3179	phosphatidylserine	abstract[175]|substance[177]	new[175]|new[177]	_	_
25-15	3180-3181	(	_	_	_	_
25-16	3182-3184	PS	abstract	new	coref	26-4
25-17	3185-3186	)	_	_	_	_
25-18	3187-3188	.	_	_	_	_

#Text=This surface expressed PS facilitates the binding of coagulation factors and by this promotes thrombin generation .
26-1	3189-3193	This	place[179]	giv[179]	_	_
26-2	3194-3201	surface	place[179]	giv[179]	_	_
26-3	3202-3211	expressed	_	_	_	_
26-4	3212-3214	PS	abstract	giv	_	_
26-5	3215-3226	facilitates	_	_	_	_
26-6	3227-3230	the	object[181]	giv[181]	_	_
26-7	3231-3238	binding	object[181]	giv[181]	_	_
26-8	3239-3241	of	object[181]	giv[181]	_	_
26-9	3242-3253	coagulation	object[181]|abstract|abstract[183]	giv[181]|new|new[183]	coref|coref	28-14[197_0]|28-14[197_0]
26-10	3254-3261	factors	object[181]|abstract[183]	giv[181]|new[183]	_	_
26-11	3262-3265	and	_	_	_	_
26-12	3266-3268	by	_	_	_	_
26-13	3269-3273	this	_	_	_	_
26-14	3274-3282	promotes	_	_	_	_
26-15	3283-3291	thrombin	place|abstract[185]	new|giv[185]	coref|coref	30-11[0_185]|30-11[0_185]
26-16	3292-3302	generation	abstract[185]	giv[185]	_	_
26-17	3303-3304	.	_	_	_	_

#Text=In addition , platelets participate in fibrin formation and regulate the process of clot retraction .
27-1	3305-3307	In	_	_	_	_
27-2	3308-3316	addition	_	_	_	_
27-3	3317-3318	,	_	_	_	_
27-4	3319-3328	platelets	object	giv	coref	29-23[206_0]
27-5	3329-3340	participate	_	_	_	_
27-6	3341-3343	in	_	_	_	_
27-7	3344-3350	fibrin	person|event[188]	new|new[188]	_	_
27-8	3351-3360	formation	event[188]	new[188]	_	_
27-9	3361-3364	and	_	_	_	_
27-10	3365-3373	regulate	_	_	_	_
27-11	3374-3377	the	abstract[189]	new[189]	_	_
27-12	3378-3385	process	abstract[189]	new[189]	_	_
27-13	3386-3388	of	abstract[189]	new[189]	_	_
27-14	3389-3393	clot	abstract[189]|object|abstract[191]	new[189]|new|new[191]	coref|coref|coref|coref	30-24|30-24[221_191]|30-24|30-24[221_191]
27-15	3394-3404	retraction	abstract[189]|abstract[191]	new[189]|new[191]	_	_
27-16	3405-3406	.	_	_	_	_

#Text=We intended to investigate whether dasatinib also affects the platelet procoagulant activity and thereby coagulation .
28-1	3407-3409	We	person	giv	ana	29-5
28-2	3410-3418	intended	_	_	_	_
28-3	3419-3421	to	_	_	_	_
28-4	3422-3433	investigate	_	_	_	_
28-5	3434-3441	whether	_	_	_	_
28-6	3442-3451	dasatinib	abstract	giv	coref	29-15
28-7	3452-3456	also	_	_	_	_
28-8	3457-3464	affects	_	_	_	_
28-9	3465-3468	the	abstract[196]	new[196]	coref	30-19[219_196]
28-10	3469-3477	platelet	object|abstract[196]	giv|new[196]	coref	29-17
28-11	3478-3490	procoagulant	person|abstract[196]	giv|new[196]	coref	29-18
28-12	3491-3499	activity	abstract[196]	new[196]	_	_
28-13	3500-3503	and	_	_	_	_
28-14	3504-3511	thereby	abstract[197]	giv[197]	_	_
28-15	3512-3523	coagulation	abstract[197]	giv[197]	_	_
28-16	3524-3525	.	_	_	_	_

#Text=For this reason , we examined the in vitro and ex vivo effects of dasatinib on platelet procoagulant response in dasatinib treated platelets of healthy volunteers and in samples derived from CML patients on dasatinib therapy .
29-1	3526-3529	For	_	_	_	_
29-2	3530-3534	this	abstract[198]	new[198]	_	_
29-3	3535-3541	reason	abstract[198]	new[198]	_	_
29-4	3542-3543	,	_	_	_	_
29-5	3544-3546	we	person	giv	ana	30-1
29-6	3547-3555	examined	_	_	_	_
29-7	3556-3559	the	_	_	_	_
29-8	3560-3562	in	_	_	_	_
29-9	3563-3568	vitro	_	_	_	_
29-10	3569-3572	and	_	_	_	_
29-11	3573-3575	ex	_	_	_	_
29-12	3576-3580	vivo	abstract[200]	new[200]	_	_
29-13	3581-3588	effects	abstract[200]	new[200]	_	_
29-14	3589-3591	of	abstract[200]	new[200]	_	_
29-15	3592-3601	dasatinib	abstract[200]|abstract	new[200]|giv	coref	29-21
29-16	3602-3604	on	_	_	_	_
29-17	3605-3613	platelet	object|abstract[204]	giv|giv[204]	coref|coref	30-19|30-19
29-18	3614-3626	procoagulant	person|abstract[204]	giv|giv[204]	coref	30-20
29-19	3627-3635	response	abstract[204]	giv[204]	_	_
29-20	3636-3638	in	abstract[204]	giv[204]	_	_
29-21	3639-3648	dasatinib	abstract[204]|person	giv[204]|giv	coref	29-35
29-22	3649-3656	treated	_	_	_	_
29-23	3657-3666	platelets	object[206]	giv[206]	coref	30-34[223_206]
29-24	3667-3669	of	object[206]	giv[206]	_	_
29-25	3670-3677	healthy	object[206]|person[207]	giv[206]|new[207]	_	_
29-26	3678-3688	volunteers	object[206]|person[207]	giv[206]|new[207]	_	_
29-27	3689-3692	and	_	_	_	_
29-28	3693-3695	in	_	_	_	_
29-29	3696-3703	samples	object	new	_	_
29-30	3704-3711	derived	_	_	_	_
29-31	3712-3716	from	_	_	_	_
29-32	3717-3720	CML	abstract|person[210]	giv|giv[210]	_	_
29-33	3721-3729	patients	person[210]	giv[210]	_	_
29-34	3730-3732	on	person[210]	giv[210]	_	_
29-35	3733-3742	dasatinib	person[210]|abstract|abstract[212]	giv[210]|giv|new[212]	_	_
29-36	3743-3750	therapy	person[210]|abstract[212]	giv[210]|new[212]	_	_
29-37	3751-3752	.	_	_	_	_

#Text=We found that at therapeutic concentration dasatainib , but not nilotinib , has a strong inhibitory effect on platelet procoagulant activity and on clot retraction both in non activated as well as in convulxin activated platelets .
30-1	3753-3755	We	person	giv	_	_
30-2	3756-3761	found	_	_	_	_
30-3	3762-3766	that	_	_	_	_
30-4	3767-3769	at	_	_	_	_
30-5	3770-3781	therapeutic	abstract[214]	new[214]	_	_
30-6	3782-3795	concentration	abstract[214]	new[214]	_	_
30-7	3796-3806	dasatainib	abstract[214]	new[214]	_	_
30-8	3807-3808	,	_	_	_	_
30-9	3809-3812	but	_	_	_	_
30-10	3813-3816	not	_	_	_	_
30-11	3817-3826	nilotinib	substance	giv	_	_
30-12	3827-3828	,	_	_	_	_
30-13	3829-3832	has	_	_	_	_
30-14	3833-3834	a	abstract[216]	giv[216]	_	_
30-15	3835-3841	strong	abstract[216]	giv[216]	_	_
30-16	3842-3852	inhibitory	abstract[216]	giv[216]	_	_
30-17	3853-3859	effect	abstract[216]	giv[216]	_	_
30-18	3860-3862	on	abstract[216]	giv[216]	_	_
30-19	3863-3871	platelet	abstract[216]|object|abstract[219]	giv[216]|giv|giv[219]	_	_
30-20	3872-3884	procoagulant	abstract[216]|person|abstract[219]	giv[216]|giv|giv[219]	_	_
30-21	3885-3893	activity	abstract[216]|abstract[219]	giv[216]|giv[219]	_	_
30-22	3894-3897	and	_	_	_	_
30-23	3898-3900	on	_	_	_	_
30-24	3901-3905	clot	object|abstract[221]	giv|giv[221]	_	_
30-25	3906-3916	retraction	abstract[221]	giv[221]	_	_
30-26	3917-3921	both	abstract[221]	giv[221]	_	_
30-27	3922-3924	in	_	_	_	_
30-28	3925-3928	non	_	_	_	_
30-29	3929-3938	activated	_	_	_	_
30-30	3939-3941	as	_	_	_	_
30-31	3942-3946	well	_	_	_	_
30-32	3947-3949	as	_	_	_	_
30-33	3950-3952	in	_	_	_	_
30-34	3953-3962	convulxin	person|object[223]	new|giv[223]	_	_
30-35	3963-3972	activated	object[223]	giv[223]	_	_
30-36	3973-3982	platelets	object[223]	giv[223]	_	_
30-37	3983-3984	.	_	_	_	_
